March Biosciences develops CAR‑T cell therapies for hard‑to‑treat hematologic cancers, focusing on target unlocking without additional gene editing. The company emphasizes high cell quality and a streamlined manufacturing process to produce consistent, robust CAR‑T products. Its lead candidate, MB‑105, targets CD5 for relapsed/refractory T‑cell lymphoma.
Funding
$33.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with relapsed or refractory T-cell lymphoma face limited therapeutic options and poor survival rates. Targeted drug development for this indication is challenging due to on-target, off-tumor toxicity issues, leaving a significant unmet need for effective treatments.
Solution
March Biosciences is developing CAR T-cell therapies specifically engineered to target hematological cancers, with an initial focus on T-cell lymphoma. Their approach prioritizes maintaining high cell quality through a streamlined manufacturing process that minimizes cell manipulation. By combining biological and engineering insights, March Biosciences aims to unlock new target spaces without the complexity of additional gene editing, ultimately improving outcomes for patients with limited treatment options. Their lead candidate, MB-105, is a CD5 CAR T-cell therapy currently in clinical development.
Target Audience
The primary target audience includes patients with relapsed or refractory T-cell lymphoma and the clinicians who treat them.
Features
- CD5-targeted CAR T-cell therapy designed for T-cell lymphomas
- Streamlined manufacturing process focused on maintaining high cell quality and minimizing cell manipulation
- Target-unlock approach leveraging biological and engineering insights without additional gene editing
- MB-105 is currently in clinical development